Bristol-Myers shareholders approve $74B Celgene deal

Despite pushback from several investors, Bristol-Myers Squibb shareholders voted in favor of its $74 billion acquisition of cancer drugmaker Celgene, according to CNBC.

The deal, announced in January, faced criticism from Bristol-Myers shareholders from the start. In February, Hedge funds Wellington Management and Starboard came out against the deal, arguing it required Bristol-Myers shareholders to assume too much risk. Starboard eventually ended its fight against the deal.

More than 70 percent of eligible shareholders voted to approve the deal April 12.

Together, the companies will have nine products with more than $1 billion in annual sales, including two top-selling cancer drugs. In the first nine months of 2018, Celgene's myeloma drug, Revlimid, had $7.1 billion in sales, and Bristol-Myers' lung-cancer treatment, Opdivo, had $4.9 billion in sales.

The drugmakers said that their combined pipeline  includes six near-term product launches, which could generate more than $15 billion in revenue.

The deal is expected to close in the third quarter of this year.

More articles on pharmacy:
PBM hearing should prompt bill to ban 'secrecy' in drug industry, senator says
Republicans tell drugmakers that complying with House probe could hurt their stock prices
Hawaii primary care network opens in-house pharmacy

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers